Evidence map›Paper›PMID 20472937›Full record

Trial reportThe New England journal of medicine2010

Target ranges of oxygen saturation in extremely preterm infants.

SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Waldemar A Carlo, Neil N Finer, Michele C Walsh, Wade Rich, Marie G Gantz, Abbot R Laptook, Bradley A Yoder, Roger G Faix, Abhik Das and 21 more

8 registry-linked trialsOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The New England journal of medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 8 registered trials, which are not on this map. Cited by 336 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
336citing papers in PubMed, 7 pooled it
53.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00233324 phase3completednot on this map

Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants

TypeinterventionalSponsorNICHD Neonatal Research NetworkRan2005 to 2016Enrolled1,316ConditionsInfant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature BirthArmsSurfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%
NCT03149731 unknown statusnot on this mapstarted 2017, after this paper: background citation

Monitoring of Cerebral and Abdominal Tissue Oxygen Saturation in Neonates

TypeobservationalSponsorXijing HospitalRan2017 to 2018Enrolled120ConditionsEstablish the Incidence Rate of Abdominal and Cerebral Hyperoxemia and Hypoxemia Events in Neonates at BirthArmsNIRS
NCT03865069 nacompletednot on this mapstarted 2019, after this paper: background citation

Comparison of Automated Oxygen Control (Closed Loop Inspired Oxygen:CLiO2™) With and Without Automated Pressure Control (Volume Guarantee®) in Preterm Ventilated Infants: A Crossover Study (CLIO-VG Study)

TypeinterventionalSponsorSouth Tees Hospitals NHS Foundation TrustRan2019 to 2020Enrolled19ConditionsOxygen Saturation Targetting in Preterm Ventilated InfantsArmsMode of ventilation (Volume Guarantee)®, Mode of ventilation (Volume control Ventilation)
NCT04223258 nacompletednot on this mapstarted 2020, after this paper: background citation

Automatic Oxygen Control for Reducing Extremes of Oxygen Saturation (AreOS): A Randomised Control Trial

TypeinterventionalSponsorSouth Tees Hospitals NHS Foundation TrustRan2020 to 2022Enrolled44ConditionsPrematurityArmsAutomatic Oxygen control, Manual Oxygen Control
NCT04534959 phase3active not recruitingnot on this mapstarted 2020, after this paper: background citation

Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients (SAVE-O2)

TypeinterventionalSponsorUniversity of Colorado, DenverRan2020 to 2025Enrolled6,000ConditionsCritical Illness, Wounds and Injury, Disease Attributes, Pathologic ProcessesArmsTargeting Normoxemia (SpO2 90-96%, PaO2 60-100 mmHg)
NCT04534972 phase3active not recruitingnot on this mapstarted 2021, after this paper: background citation

Strategy to Avoid Excessive Oxygen in Major Burn Patients (SAVE-O2)

TypeinterventionalSponsorUniversity of Colorado, DenverRan2021 to 2025Enrolled2,000ConditionsCritical Illness, Wounds and Injury, Disease Attributes, Pathologic ProcessesArmsTargeting Normoxemia (SpO2 90-96%, PaO2 60-100 mmHg)
NCT04687618 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Randomized Control Trial of Oxygen Assist Module in Preterm Infants on High Flow Nasal Cannula Support (ROAM)

TypeinterventionalSponsorSouth Tees Hospitals NHS Foundation TrustRan2021 to 2023Enrolled60ConditionsPreterm BirthArmsHigh Flow Nasal Cannula withAutomatic control of FiO2 using OAM, High Flow Nasal Cannula with manual control of FiO2
NCT06622161 nacompletednot on this mapstarted 2024, after this paper: background citation

Automated Oxygen Control in Preterm Babies on Respiratory Support: A Randomized Cross Over Study

TypeinterventionalSponsorAga Khan University Hospital, PakistanRan2024 to 2025Enrolled26ConditionsPretermArmsautomated oxygen vs manual oxygen
3 · Its place in the literature

Who cites it

336 citing papers in PubMed, 7 syntheses or guidelines pooled it, 935 citations in OpenAlex.

  1. Automated oxygen delivery for preterm infants with respiratory dysfunction.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Thresholds for surfactant use in preterm neonates: a network meta-analysis.Archives of disease in childhood. Fetal and neonatal edition · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Time spent within the SpOBMJ open respiratory research · 2026
    Trial
  9. Trial
  10. Maternal hypertensive disorders and survival without major morbidities among extremely low gestation newborns.Journal of perinatology : official journal of the California Perinatal Association · 2023
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Achieved oxygen saturations and retinopathy of prematurity in extreme preterms.Archives of disease in childhood. Fetal and neonatal edition · 2020
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

276 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 1 institution in 2 countries.

SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network
Waldemar A Carlo
Neil N Finer
Michele C Walsh
Wade Rich
Marie G Gantz
Abbot R Laptook
Bradley A Yoder
Roger G Faix
Abhik Das
W Kenneth Poole
Kurt Schibler
Nancy S Newman
Namasivayam Ambalavanan
Ivan D Frantz
Anthony J Piazza
Pablo J Sánchez
Brenda H Morris
Nirupama Laroia
Dale L Phelps
Brenda B Poindexter
C Michael Cotten
Krisa P Van Meurs
Shahnaz Duara
Vivek Narendran
Beena G Sood
T Michael O'Shea
Edward F Bell
Richard A Ehrenkranz
Kristi L Watterberg
Rosemary D Higgins
Research Network (United States) · US

Funding

Neonatal Research Network Data Coordinating Center (DCC)U10HD036790 · NICHD · RESEARCH TRIANGLE INSTITUTE · PI DAS, ABHIK · 2008 to 2017
$62.3M
YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
WORKER PROTECTION AGAINST AIRBORNE INFLUENZA - A PILOT STUDYM01RR007122 · NCRR · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HOLMES, ROSS P · 1992 to 2010
$35.2M
UNIVERSITY OF IOWA CTSA FOR PEDIATRIC RESEARCHUL1RR024979 · NCRR · UNIVERSITY OF IOWA · PI ROSENTHAL, GARY E · 2007 to 2011
$31.8M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1UL1RR025744 · NCRR · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2008 to 2011
$22.4M
VITAMIN K DEFICIENCY IN CHOLESTATIC LIVER DISEASEM01RR008084 · NCRR · CINCINNATI CHILDRENS HOSP MED CTR · PI STRAUSS, ARNOLD W · 1994 to 2009
$20.6M
XOMAZYME-CD5 PLUS THERAPY IN RHEUMATOID ARTHRITISM01RR000030 · NCRR · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 1985 to 2006
$20.0M
University of New Mexico Clinical and Translational Science CenterUL1TR000041 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LARSON, RICHARD S · 2012 to 2014
$9.8M
NICHD Cooperative Multicenter Neonatal Research NetworkU10HD021385 · NICHD · WAYNE STATE UNIVERSITY · PI SHANKARAN, SEETHA · 1991 to 2015
$8.7M
NCATS NIH HHS UL1 TR000041NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR001449NCRR NIH HHS M01 RR000030NCRR NIH HHS M01 RR006022NCRR NIH HHS M01 RR007122NCRR NIH HHS M01 RR008084NCRR NIH HHS M01 RR016587NCRR NIH HHS M01 RR125NCRR NIH HHS M01 RR16587NCRR NIH HHS M01 RR30NCRR NIH HHS M01 RR32NCRR NIH HHS M01 RR39NCRR NIH HHS M01 RR44NCRR NIH HHS M01 RR54NCRR NIH HHS M01 RR59NCRR NIH HHS M01 RR6022NCRR NIH HHS M01 RR633NCRR NIH HHS M01 RR64NCRR NIH HHS M01 RR70NCRR NIH HHS M01 RR7122NCRR NIH HHS M01 RR750NCRR NIH HHS M01 RR80NCRR NIH HHS M01 RR8084NCRR NIH HHS M01 RR997NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1 RR024979NCRR NIH HHS UL1 RR025008NCRR NIH HHS UL1 RR025744NCRR NIH HHS UL1 RR24139NCRR NIH HHS UL1 RR24979NCRR NIH HHS UL1 RR25008NCRR NIH HHS UL1 RR25744NICHD NIH HHS K23 HD041423NICHD NIH HHS U10 HD021364NICHD NIH HHS U10 HD021373NICHD NIH HHS U10 HD021385NICHD NIH HHS U10 HD021397NICHD NIH HHS U10 HD027851NICHD NIH HHS U10 HD027853NICHD NIH HHS U10 HD027856NICHD NIH HHS U10 HD027871NICHD NIH HHS U10 HD027880NICHD NIH HHS U10 HD027904NICHD NIH HHS U10 HD034216NICHD NIH HHS U10 HD036790NICHD NIH HHS U10 HD040461NICHD NIH HHS U10 HD040492NICHD NIH HHS U10 HD040498NICHD NIH HHS U10 HD040521NICHD NIH HHS U10 HD040689NICHD NIH HHS U10 HD053089NICHD NIH HHS U10 HD053109NICHD NIH HHS U10 HD053119NICHD NIH HHS U10 HD053124NICHD NIH HHS U10 HD21364NICHD NIH HHS U10 HD21373NICHD NIH HHS U10 HD21385NICHD NIH HHS U10 HD21397NICHD NIH HHS U10 HD27851NICHD NIH HHS U10 HD27853NICHD NIH HHS U10 HD27856NICHD NIH HHS U10 HD27871NICHD NIH HHS U10 HD27880NICHD NIH HHS U10 HD27904NICHD NIH HHS U10 HD34216NICHD NIH HHS U10 HD36790NICHD NIH HHS U10 HD40461NICHD NIH HHS U10 HD40492NICHD NIH HHS U10 HD40498NICHD NIH HHS U10 HD40521NICHD NIH HHS U10 HD40689NICHD NIH HHS U10 HD53089NICHD NIH HHS U10 HD53109NICHD NIH HHS U10 HD53119NICHD NIH HHS U10 HD53124NICHD NIH HHS UG1 HD027851NICHD NIH HHS UG1 HD027880NICHD NIH HHS UG1 HD034216NICHD NIH HHS UG1 HD040492NICHD NIH HHS UG1 HD053089NICHD NIH HHS UG1 HD053109
6 · The paper itself

Abstract

backgroundPrevious studies have suggested that the incidence of retinopathy is lower in preterm infants with exposure to reduced levels of oxygenation than in those exposed to higher levels of oxygenation. However, it is unclear what range of oxygen saturation is appropriate to minimize retinopathy without increasing adverse outcomes.

methodsWe performed a randomized trial with a 2-by-2 factorial design to compare target ranges of oxygen saturation of 85 to 89% or 91 to 95% among 1316 infants who were born between 24 weeks 0 days and 27 weeks 6 days of gestation. The primary outcome was a composite of severe retinopathy of prematurity (defined as the presence of threshold retinopathy, the need for surgical ophthalmologic intervention, or the use of bevacizumab), death before discharge from the hospital, or both. All infants were also randomly assigned to continuous positive airway pressure or intubation and surfactant.

resultsThe rates of severe retinopathy or death did not differ significantly between the lower-oxygen-saturation group and the higher-oxygen-saturation group (28.3% and 32.1%, respectively; relative risk with lower oxygen saturation, 0.90; 95% confidence interval [CI], 0.76 to 1.06; P=0.21). Death before discharge occurred more frequently in the lower-oxygen-saturation group (in 19.9% of infants vs. 16.2%; relative risk, 1.27; 95% CI, 1.01 to 1.60; P=0.04), whereas severe retinopathy among survivors occurred less often in this group (8.6% vs. 17.9%; relative risk, 0.52; 95% CI, 0.37 to 0.73; P<0.001). There were no significant differences in the rates of other adverse events.

conclusionsA lower target range of oxygenation (85 to 89%), as compared with a higher range (91 to 95%), did not significantly decrease the composite outcome of severe retinopathy or death, but it resulted in an increase in mortality and a substantial decrease in severe retinopathy among survivors. The increase in mortality is a major concern, since a lower target range of oxygen saturation is increasingly being advocated to prevent retinopathy of prematurity. (ClinicalTrials.gov number, NCT00233324.)

Indexed as

Infant MortalityContinuous Positive Airway PressureFemaleHospital MortalityHumansInfant, NewbornInfant, PrematureIntubation, IntratrachealKaplan-Meier EstimateMaleOximetryOxygenOxygen Inhalation TherapyProportional Hazards ModelsPulmonary SurfactantsReference ValuesOxygenPulmonary Surfactants

Identifiers

PMID20472937
PMCPMC2891970
OpenAlexW2210128369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

and 2 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.